A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis

BACKGROUND: Rituximab (RTX) and ocrelizumab (OCR) are two anti-CD20 biologics used in MS; however, comparisons on safety and efficacy are rare. OBJECTIVE: To compare treatment outcomes over the first year with RTX and OCR. METHODS: Retrospective cohort study comprising MS patients initiating RTX at...

Descripción completa

Detalles Bibliográficos
Autores principales: Evertsson, Björn, Hoyt, Tammy, Christensen, Angel, Nimer, Faiez AL, Foley, John, Piehl, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556182/
https://www.ncbi.nlm.nih.gov/pubmed/33110619
http://dx.doi.org/10.1177/2055217320964505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556182/
https://www.ncbi.nlm.nih.gov/pubmed/33110619
http://dx.doi.org/10.1177/2055217320964505

Ejemplares similares